Interim Report for the period July – September 2023

LEQEMBI launched in the USEvents during the third quarter 2023 · In July, the FDA approved LEQEMBI® for the treatment of Alzheimer’s disease in the US and the Centers for Medicare and Medicaid Services, CMS, announced that LEQEMBI will be reimbursed according to the FDA approved label · In September, LEQEMBI was approved for the treatment of Alzheimer's disease in Japan, which entitled BioArctic to a milestone payment of EUR 17 M, equivalent to SEK 201.0 M · The board has decided to initiate a Phase 2a study of exidavnebab (BAN0805) in Parkinson's disease. The study is expected